Prevalence of Posttranscatheter Aortic Valve Implantation Vascular Complications in Real Life

Table 4

Stepwise logistic regression studying the association between vascular complications, predictors, and adverse outcomes.

Variables	OR	95% CI	value
Smoking	1.67	[0.58; 4.77]	0.33
Hypertension	1.42	[0.97; 2.08]	0.06
NYHA class	0.78	[0.6; 1.02]	0.07
TAVI indication	0.54	[0.29; 0.99]	0.04
Prior valvuloplasty	1.29	[0.79; 2.1]	0.3
Carotid disease	1.57	[0.71; 3.45]	0.26
BMI	1.02	[0.98; 1.05]	0.3
SAPT	1.17	[0.8; 1.7]	0.4
DAPT	0.73	[0.46; 1.16]	0.18
Right access site	0.6	[0.37; 0.99]	0.04
Introducer sheath size 14 Fr	0.63	[0.45; 0.89]	0.009
Valve types	0.82	[0.6; 1.1]	0.22
Procedure duration	1.8	[1.2; 2.8]	0.005
Death	1.63	[0.65; 4.09]	0.29
Bleeding	2.57	[1.8; 3.6]	<0.001
CCU stay (>24 hours)	2	[1.4; 3]	<0.001

^∗NYHA: New York Heart Association; BMI: body mass index; SAPT: single antiplatelet therapy; DAPT: dual antiplatelet therapy; TAVI: transcatheter aortic valve implantation; CCU: cardiac care unit.